Immune Suppression in
Auto-Immune Hemolytic Anemia*
JOHN H. MOON

Division of Hematology,
Medical College of Virginia,
Richmond 23219

The acquired auto-immune hemolytic anemias represent a diversity of disease states in which the most
constant immunologic finding is a positive direct
anti-human globulin test (van Loghem, 1965; Swisher
et al, 1965). This is true of the symptomatic variety
of acquired hemolytic anemia as well as the idiopathic
form. The positive Coomb's test has been seen in
association with primary atypical pneumonias, occasionally in favism, in some bacterial and drug induced hemolytic anemias, in patients with malignancies
of the lymphoid tissues, and in collagen-vascular disorders-chiefly SLE.
The original hope that the direct Coomb's test would
be negative in all forms of hereditary hemolytic disease
and thus differentiate them from acquired forms of
hemolytic anemia has not been borne out.
Acquired auto-immune hemolytic anemias vary
widely in the severity of the hemolysis, in the association of additional pathologic states and in the comparative clinical influence of these factors. Those cases
of auto-immune hemolytic anemia that are associated
with self-limiting viral diseases such as infectious
mononucleosis, measles or bacterial infections, usually
subside with the primary disease. Forms· of Coomb's
positive hemolytic anemias associated with drug therapy can usually be eliminated by withholding the
offending drug. In instances where the Coomb's
positive hemolytic anemia is associated with benign or
malignant tumors or cysts, surgical correction of the
abnormality may result in permanent hematologic and
serologic remission. It has also been observed that a
positive Coomb's test may occur in association with
pernicious anemia, folic acid deficiency and iron deficiency anemia. In these circumstances, replacement
of the specifically deficient material may result in complete remission of the hematologic abnormality. This
discussion will concern itself primarily with the idiopathic disease, since immunosuppression is not necessary or desirable in most of the symptomatic varieties.
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Since the diagnosis of an auto-immune hemolytic
anemia of the idiopathic variety is tied to the exclusion of recognizable causative disease, the frequency
with which the diagnosis is made will first depend on
the aggressiveness of the attending physician in looking for secondary causes and secondly, the nature of
the patient population. Since the disease has a peak
incidence in the fourth through seventh decades, a
large pediatric population would diminish the incidence. Likewise, since about 60 percent of the patients
in reported series are women, a largely male clinic or
hospital population would have a similar effect. No
racial discrepancies have been noted to date. In Dacie's
series (1969) followed over a 20 year period, 111/ 210
or 52 percent adult patients with a positive direct
Coomb's test were classified as idiopathic, whereas
only 18.2 percent of Pirofsky's 234 cases were idiopathic ( 1969). A positive direct Coomb's test is, of
course, central to the diagnosis of auto-immune hemolytic anemia although a positive direct Coomb's may
be present for years with hemolysis.
The demonstration that the globulins coating the
red cells are "true" antibodies is now generally accepted with the proviso that the coating of the red
cells with a protein giving rise to a positive antiglobulin reaction does not necessarily mean that the reacting substance is an erythrocyte antibody. It may even
be complement absorbed as a result of antibody activity. By performing a gamma globulin neutralization
test one can elucidate whether the coating globulin of
the erythrocyte is a gamma globulin, complement or
mixed type. Further evaluation of the protein can be
done with antiglobulin sera specific for lgG, lgM, or
IgA. The great majority of auto-immune hemolytic
anemias will have lgG antibody.
The cardinal points which identify the coating
globulins as antibodies are their transferability to normal red cells; the frequent presence in serum of similar globulins which can be absorbed by normal cells;
and in many instances, their ability to react with specifically identifiable red cell antigens. For instance, in
patients who form warm antibodies, it is often possible
to demonstrate a clear specificity for one or more Rh
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antigens, but the nature of specificity of other antibodies which do not have affinity with Rh antibodies
is yet unknown. It appears probable that an antibody
reacting indifferently with all human cells may be involved. Although the etiology of the auto-immune
hemolytic anemias remains obscure, current theory
(Parker and Vavra, 1969) surmises that somatic mutation leads to the development of forbidden clones of
antibody forming cells which are not susceptible to,
and escape from, the normal homeostatic mechanisms
which prevent auto-antibody formation . The association of auto-immune hemolytic anemias with other
diseases thought to be of an auto-immune nature, such
as disseminated lupus erythematosis and ulcerative
colitis, lends unity to this concept. Chronic lymphocytic leukemia and lymphosarcoma may represent
malignancies of potential antibody forming cells in
which the tumor cells, in some instances, retain their
ability to form antibodies, particularly abnormal ones
which react with erythrocytes. Another possibility is
that the antibodies primarily formed against the abnormal neoplastic lymphoid cells act as antigens; the
antibodies which cross-react with red cells. It also
seems conceivable that the malignant lymphomas
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represent an enormous monoclonal proliferation of
lymphoid cells which displace the immunologically
competent cells and interfere with the delicate balance
between the two. This allows the development of a
clone of auto-antibody forming cells. Whichever of
these mechanisms ultimately proves to be true, the
current therapy for auto-immune hemolytic anemias
of a sufficient degree of severity to require treatment
involves attempts at immunological manipulation.
Cu rre nt Con cep t of the Immu ne Respon se

The current concept of the immune response (Fig
l) is divided into afferent, recognition, stimulatory and
effector phases. All phases of this scheme can be
manipulated to produce immunologic tolerance, as we
shall see.
( 1) In the afferent phase it is believed that the antigen is processed by macrophages into highly immunogenic complexes with RA and other cellular constituents.
(2) In the recognition phase the macrophage transmits messenger RNA to "antigen sensitive cells" which
have the morphologic appearance of a small lymphocyte. These cells arise from stem cells in the marrow
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Fig I-The four phases of the immune response (modified from D avis, et al; Microbiology, 1967).
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where they are incapable of responding to antigen.
Upon leaving the marrow they migrate to the thymus
where partial maturation takes place and then seed
peripheral lymphoid tissue where they acquire immunologic competence. Stimulation of these "antigen
sensitive cells" appears to be confined to lymphoid
organs. They do not in themselves produce antibody,
but they give rise to clones of antibody producing
cells as well as to additional antigen sensitive cells.
( 3) In the stimulatory phase exposure to antigen
initiates an immunologic response after a latent period
of four to 24 hours. Mature antibody processing cells
appear to arise from a large immunoblast (hemacytoblast) and reproduce rapidly. Serum antibody arises
logarithmically and gradually declines. Small lymphocytes are also formed, committed to react specifically
with antigen. They seem to be the primary mediators
of cellular immunity and probably carry long term
immunologic memory.
( 4) In the effector phase the small lymphocytes are
responsible for such forms of hypersensitivity as allograft rejection, and contact skin sensitivity.
Responses attributable to serum antibody include
local and systemic anaphylaxis, Arthus phenomenon,
hemolytic anemia and thrombopenia.
Approaches to lmmunosuppression
In clinical immunosuppression the number of options available to the clinician is somewhat restricted
by the clinical setting. Since the immune response in
auto-immune hemolytic anemia is mediated by humoral antibody, attempts at immunosuppression should
be so directed.
Table I shows the theoretical areas where immunosuppression might be possible in immuno hemolytic
anemia. Administration of antigen might be considered
as analagous to desensitization of patients with allergic
asthma. Since the nature of the erythrocyte antigen is
unknown, this approach does not seem feasible at
present. Administration of specific antibody as a form
of immunosuppression has received renewed interest
as a result of the successful use of Rh antibody in the
prophylaxis of erythroblastosis. It seems dubious that
such an approach would prove successful in autoimmune hemolytic anemia for a variety of reasons.
I would like to discuss the types of immunosuppression which have been attempted in auto-immune
hemolytic anemia, paying particular attention to those
methods which are most commonly used in treatment
today (Table II).

Surgical Ablation of Lymphoid Tissue
One of the four major approaches to immunosuppression has been that of surgical abl~tion. Sple~ec
tomy, of course, is the oldest form of .1mmun.olog1cal
manipulation that has been attempted m autoimmune

TABLE I
Approaches to immunosuppression
1. Administration of antigen

2.
3.
4.
5.
6.

Administration of specific antibody
Administration of antilymphocyte serum
Cytotoxic drugs
Radiation
Surgical ablation of lymphoid tissue

TABLE II
Approaches to immunosuppression in idiopathic autoimmune hemolytic anemia
Surgical ablation of lymphoid tissue
A. Splenectomy
B. Thymectomy
C. Thoracic duct drainage
II. Administration of cytotoxic drugs
A. Corticosteroids
B. Alkylating agents
C. Purine antagonists
III. Radiation
A. Total body
B. Local
1. spleen
2. Lymph nodes
I.

hemolytic anemias. The rational behind its first application in 1911 by Michelle was a result of Banti's work
incriminating the spleen as a primary site of blood
destruction. The mechanistic concept of its function in
auto-immune hemolytic anemia is probably still a
prime reason for its removal; but it is included in the
list of immunological manipulations because of the
evidence showing splenic hyperplasia, particularly an
increased production of lymphocytes and plasma cells,
in the spleen. This suggests that hemolysis can potentiate the ability of the spleen to engage in antibody
production. Jandl ( 1965) speculated that the enhanced
immunologic reactivity of the hyperplastic spleen could
take two pathways. In one it could initiate immunologic
responses directed against related or coincidental antigens of the erythrocyte; in the other it could convert
reactions which were intially nonimmune into immune forms. The latter mechanism could possibly permit metabolically modified antigenic determinants to be recognized as foreign. In this manner,
it could supply the background to the auto-immune
state described as an enhanced sensitivity of antibody
forming tissues. Splenic hyperplasia creating these
two antibody producing states could result in an immune relationship which is auto-catalytic and which
would appear as an auto-immune hemolytic anemia.
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The beneficial effects of splenectomy have been amply documented in several series reported since
1911. Therapeutic response has been noted in about
70 percent of the patients treated with half of the patients apparently being cured of their disease (Allgood and Chaplin, 1967). The mortality rate, however,
of splenectomy in patients with auto-immune
hemolytic disease is high and averages about 17 percent in the series reported. There is a further increase
in mortality if splenectomy is delayed for over a year
after the onset of the disease. This high surgical mortality rate has tempered the enthusiasm for splenectomy
in most clinics.
In addition to the immediate surgical mortality of
splenectomy, the predisposition of patients with autoimmune hemolytic anemia to thrombosis may be enhanced by the thrombocytosis occurring after the
spleen is removed. In younger patients, such a thrombocytosis is usually well tolerated, but in the older
age groups with co-existing atherosclerosis, it may
constitute a major hazard to the patient's survival.
The increased frequency of overwhelming infections in
infancy following splenectomy seems to be real, but
since auto-immune hemolytic anemia occurs very
rarely in this age group, it is seldom a consideration. A
more serious difficulty following splenectomy is the hyperplasia which sometimes occurs within the reticuloendothelial cells in the liver leading to progressive hepatomegaly, liver dysfunction and death.
Responses to splenectomy in patients with autoimmune hemolytic anemias secondary to reticuloendothelial neoplasm seem to be somewhat less
frequent than in the idiopathic form of disease. Splenectomy may be of value after patients have failed
on corticosteroids, and Crosby's data suggest that the
remission rates following splenectomy in patients who
are unresponsive to steroids may be as good as those
treated de novo with splenectomy. Several authors
have emphasized criteria which may enable one to select candidates for splenectomy. Among these are the
patients with warm acting, incomplete erythrocyte
auto-antibodies and documentation of splenic sequestration. Several methods of determining significant
splenic sequestration of Cr 51 labeled red cells are in
use including those devised by Korst (1955) , Jandl
(1956), and McCurdy and Roth (1958). All suffer the
same defect, ie, they are not entirely reliable in predicting either response to splenectomy or failure of
response.
Goldberg and his associates have suggested that a
reduced Chromium 51-T 1h may be of importance in
selecting candidates for splenectomy; this seemed
to be the case in their series of 13 patients in whom
11 had good results. It is difficult to know what this
means since all patients with auto-immune hemolytic
anemia have reduced Cr51 red cell survival times and
the response rate is what one would expect. Evidence
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of sequestration of red cells in the liver is a poor prognostic sign and suggests that splenectomy will offer little benefit.
Thymectomy is an attractive approach to immunosuppression in ante-immune hemolytic anemia because
of the central role of the thymus in the maturation
of immunologically competent cells. It is also technically easier than splenectomy and should carry a lower
mortality rate. No data are available on adults treated
in this manner, but in infants there have been two remissions induced with this procedure and one failure.
Thymectomy appears to be of no value when thymoma
is associated with auto-immune hemolytic anemia.
Thoracic duct drainage seems potentially useful
because primary antigen sensitive cells and immunologic memory cells can be removed. Unfortunately,
immunologic impairment is very short lived.
Cytotoxic Drugs

The administration of cytotoxic drugs is a second
approach to immunosuppression. The inmmnosuppressive effects of corticosteroids resemble those of
x-irradiation in that they produce lymphocytolysis
particulary in the germinal centers of lymph nodes
and spleen with resultant lymphocytopenia. The mechanism by which the cell damage is effected is unknown.
They are also active in suppression of delayed hypersensitivity but their effect on serum antibody synthesis is less impressive.
Because of the high surgical mortality associated
with splenectomy in auto-immune hemolytic disease,
the observed lympholytic activity of adrenocorticoids
was investigated in 1951 by Dameshek in auto-immune
hemolytic anemias.
In a series reported in 1956, Dameshek and
Komninos claimed that 90 percent of the cases of autoimmune hemolytic anemia would show an initial therapeutic response to corticosteroids. Of these, 65 percent
were complete remissions and in an additional 25 percent a definite response was obtained. Two-thirds of the
cases, however, relapsed when corticosteroids were
discontinued. Subsequent series have shown similar
results. Horster reported a 6.8 percent cure rate with
corticosteroids, and remissions lasting over a year in
about a third of the cases after discontinuation of
corticosteroid therapy. About half of the patients
could be maintained in remission only while corticosteroids were continued. Pirofsky's data suggests
that the corticosteroids, too, are less effective in the
auto-immune hemolytic anemias associated with
reticule-endothelial malignancy. The dosage of corticosteroids necessary to induce remission has been variable in the series reported but in the average adult,
300 mg of cortisone per day or it's equilvalent of prednisone, triamcinolone, or dexamethasone, appear to
be an effective dose level. If using corticosteroids is
effective, time of onset of the evidence for reduced
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hemolysis is rapid. Response is usually clearly apparent within the first one to two weeks, although a few
patients will respond as long as 21 days after therapy
is begun. In the patients who respond slowly, the
response tends to be less good and it is difficult to
remove such patients from steroid coverage.
Hematologic remission may occur while the direct
anti-globulin tests remain positive. In idiopathic autoimmune hemolytic anemias, there may be reduction
in spleen size, although this effect is not as marked in
the symptomatic varieties of the disease. Since the
side-effects of steroids are not inconsiderable, reductions from the high dose levels initially used, should
be made as soon as possible, and the minimally effective dose of corticosteroid should be used as the maintenance dose. Even with maintenance, a significant
number of relapses will occur within the first six
months, although the relapse is usually of gradual onset. If the patient is being seen at frequent intervals,
there is normally sufficient warning to increase the
amount of steroid. In a few patients, prednisone may
gradually be discontinued over a period of five or six
months and the patients will remain in remission.
Alkylating agents include such compounds as the
nitrogen mustards, sulfur mustards, sulfonate esters
and ethylenimines. They are chemically highly reactive and are capable of combining irreversibly with
DNA, proteins and other essential macromolecules in
the cell.
Cyclophosphamide, a latent compound activated in
vivo after tissue phosphorylases cleave the cyclic
phosphamide moiety to expose the alkylating radicals, has been shown to be a very promising immunosuppressive agent. It appears to be capable of reducing the antigen sensitive cell population, blocking
cellular proliferation during the inductive phase and
is ever active in reducing antibody synthesis. Hersh
found it to be the most effective immunosuppressive
agent among the various alkylating agents. I am unaware of any published reports on its effectiveness in
auto-immune hemolytic anemias, although there are
isolated reports of remission induced by other alkylating agents (Taylor, 1963).
Purine and pyrimidine antagonists are another approach included among the cytotoxic drugs. In 1957,
Stertzle and Holub suggested that 6-Mercapto-purine
(6-MP) might interfere with antibody synthesis, but
were unable to confirm it in the test system that they
were using. This was independently confirmed in extensive studies by Schwartz and Dameshek (Schwartz
and Dameshek, 1959; Dameshek and Schwartz, 1960;
Schwartz, Eisner and Dameshek, 1959; Schwartz and
Dameshek, 1960) who demonstrated that 6-MP could
suppress antibody formation in rabbits immunized with
Bovine albumin. In addition, 6-MP apparently could
induce a state of immunologic unresponsiveness in
adult rabbits and could suppress transplantation rejec-

tion of skin graft although not completely at tolerated
doses. Further studies on the mechanism by which 6MP was capable of inducing this effect led to the conclusion that the drug had its primary effect on the lymphoid hemocytoblast (immunoblast) and morphologic
studies of lymph nodes subsequent to 6-MP after a
homograft administration revealed extensive disruption
of the lymphoid follicles (Andre et al, 1962). Borel also
showed suppression of IgG response with prolonged
administration. Studies were extended (Schwartz
and Dameshek, 1962) to include cases of human auto-immune hemolytic anemias treated with
6-MP or Thioguanine with a favorable effect in three
of six cases. 6-MP and thioguanine have been sporadically reported since (Demis, Brown and Crosby,
1964; Shearn, 1965 ; Hitzig and Massimo, 1966) to
cause remissions in auto-immune hemolytic anemia.
The primary limiting factors to the administration of
these agents is bone marrow toxicity (Demis, Brown
and Crosby, 1964). Azothiaprine (an imidazole subsituted 6-MP) is converted to 6-MP in vivo. It has
been used in the auto-immune hemolytic anemias alone
and in combination with corticosteroids with some success. Its spectrum of immunosuppression is similar to
6-MP but it appears to have a better therapeutic ratio
(Frisch and Davis, 1962; Frisch, Davis and Milstein, 1962) and produces less bone marrow suppression. It also produces fewer G.I. symptoms when
given orally.
It seems probable that these agents do not show
cross resistance with corticosteroids, and failure on the
latter does not necessarily militate against induction
of remission with the former. Response rates are difficult to access on the basis of the limited number of
cases reported, but the drugs are somewhat less effective than corticosteroids. This may merely reflect the
fact that the patients are further advanced in their
disease.
Fig 2 shows the clinical course of a 79-year old
white man, who was first seen here in August 1964
for treatment of progressive anemia of four months'
duration. Physical examination was essentially unremarkable. His laboratory data revealed a hemo~lobin
of 7.8 gm percent, reticulocyte count 29 percent,
MCV 96, MCH 32, MCHC 34, and Bilirubin 2.2
mg percent with 0.3 mg percent direct reacting fraction. Coomb's test was weakly positive. Cold agglutinins were positive in a titre of 1 : 64. Chromium51 red
cell survival was 7 1h days, and the spleen to liver
ratio was 0. 72. This patient was started on prednisone
40 mgs per day with a prompt rise in his hemoglobin
concentration, as shown in Fig 2. His hemoglobin
was maintained well until steroid toxicity forced the
reduction of his dose of prednisone. Three months
later his hemoglobin gradually fell to levels of seven
to eight grams percent. He required an interim hospitalization in September 1966, at which time his
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Fig 2- The clinical course of a 79-year old white man being treated for progressive anemia.

hemoglobin was 8.5 gm percent, reticulocyte count
was 40 percent, cold agglutinins were positive at a
titre of 1: 1, 280, and Coomb's was strongly positive.
He was seen again in consultation and the recommendation was made that he be offered splenectomy.
Because of his age and the patient's wishes this was
not done, and he was instead started on 6-MP in a
dose of 25 mg per day, which was continued uninterruptedly until the time of his terminal hospitalization
in August 1969. We have only random blood counts
available for this period of almost five years, because
he was being followed elsewhere. He was admitted in
August 1969 because of massive G.I. bleeding. At
that time his hemoglobin concentration was 5.5 gm
percent with a reticulocyte count of 16 percent. Prednisone, which had been continued at a low dose level
of 5 mg per day was increased because of the uncertainity as to whether the marked fall in his hemoglobin concentration was the result of bleeding or an accelerated rate of hemolysis. His upper G.I. series was
normal. His barium enema revealed some diverticula
in the colon. His Coomb's test was strongly positive
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and his cold agglutinin titre was too high to read.
Serum protein electrophoretic pattern was essentially
normal, except for a questionable blip in the slow
gamma region. Immunoelectrophoretic assay of his
serum revealed an lgM level of 1,168. lgG and lgA
levels were normal. He was started on leukeran,
12 mg per day on September 11, 1969, which was
continued through October 5, 1969, when it had to be
discontinued because of leukopenia of moderate degree. His G.I. bleeding continued throughout his hospital illness, and he was transfused several times when
his hemoglobin concentration fell to dangerous levels.
It was not apparent, in this particular patient, who had
what we would classify as cold agglutinin disease, that
his immunologic process was altered either by the
long-term administration of small doses of 6-MP or by
the relatively aggressive therapy with chlorambucil at
the time of his terminal illness.

Radiation
The primary effect of total body irradiation appears
to be on DNA of lymphoid and other sensitive cells.
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Unfortunately, when used alone, high doses are required which are lethal in themselves. At present there
seems to be no place for total body irradiation in the
clinical context of auto-immune hemolytic anemias.
Local irradiation has proven to be a more effective
approach to immunosuppression. Since splenectomy
is an efficient form of treatment for autoimmune hemolytic anemia it has seemed natural to try to circumvent the surgical mortality by splenic irradiation.
Results have generally been poor. However, some
transient responses have been obtained in secondary
forms of auto-immune hemolytic anemias, particularly
those associated with malignancy of the reticuloendothelial tissues.
As far as tire lymph node is concerned, nodal irradiation seems to offer little promise in auto-immune
hemolytic anemia but there are scattered reports by
Wasserman, Brown, Eisner (Eisner, Ley and Mayer,
1967), and others of a beneficial effect on symptomatic hemolytic anemias from Hodgkin's disease to
radiation of local tumor masses.
Administration of Anti-Lymphocyte Serum

Anti-lymphocyte serum has been shown to be of
value in the treatment of the allograft rejection response but its primary effect seems to be in suppressing
cellular immunity rather than humoral. There is some
evidence that it may abolish immunologic memory and
thus might be of value in auto-immune hemolytic
anemia. We are unaware of any attempts to use the
material in the clinical setting of auto-immune hemolytic anemia.
Prognosis
The outlook in auto-immune hemolytic anemia is
unpredictable but a large number of the patients can
be controlled by judicious therapy with corticosteroids.
Despite the improvement in mortality rates since the
advent of steroids ( 46 percent Dacie's series) the mortality rates are still high-31 percent Dausset and
Columbani and 28.2 percent Allgood. If the disease
cannot be controlled with low doses of steroid which
produce minimal toxicity, splenectomy should be
done. The time at which this should be performed
will require individualization for each patient but, in
general, a failure of corticosteroid therapy at acceptable levels of toxicity will require splenectomy at four
to six months.
If splenectomy fails to halt the immune process or
cannot be done because of the patient's poor condition,
a trial of other immunosuppressive agents may be
attempted or thymectomy may be resorted to. Information at present is not firm enough to recommend a
specific line of approach. On the basis of the experimental data, drug therapy with either cyclophosphamide or azothiaprine would be my personal choice.
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